CA2827187C - Water soluble membrane proteins and methods for the preparation and use thereof - Google Patents
Water soluble membrane proteins and methods for the preparation and use thereof Download PDFInfo
- Publication number
- CA2827187C CA2827187C CA2827187A CA2827187A CA2827187C CA 2827187 C CA2827187 C CA 2827187C CA 2827187 A CA2827187 A CA 2827187A CA 2827187 A CA2827187 A CA 2827187A CA 2827187 C CA2827187 C CA 2827187C
- Authority
- CA
- Canada
- Prior art keywords
- receptors
- variant
- gpcr
- water
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- 108010052285 Membrane Proteins Proteins 0.000 title abstract description 48
- 238000002360 preparation method Methods 0.000 title abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 8
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 33
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 33
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 33
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 32
- 102000005962 receptors Human genes 0.000 claims description 31
- 108020003175 receptors Proteins 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 239000003446 ligand Substances 0.000 claims description 24
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 23
- 239000004473 Threonine Substances 0.000 claims description 23
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 19
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 15
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 15
- 229960000310 isoleucine Drugs 0.000 claims description 15
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 13
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 12
- 102000009410 Chemokine receptor Human genes 0.000 claims description 12
- 108050000299 Chemokine receptor Proteins 0.000 claims description 12
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 12
- 102000002020 Protease-activated receptors Human genes 0.000 claims description 12
- 108050009310 Protease-activated receptors Proteins 0.000 claims description 12
- 102000011923 Thyrotropin Human genes 0.000 claims description 12
- 108010061174 Thyrotropin Proteins 0.000 claims description 12
- 229950006323 angiotensin ii Drugs 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 12
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 11
- 125000001165 hydrophobic group Chemical group 0.000 claims description 11
- 239000004474 valine Substances 0.000 claims description 11
- 101800001982 Cholecystokinin Proteins 0.000 claims description 10
- 102100025841 Cholecystokinin Human genes 0.000 claims description 10
- 229940107137 cholecystokinin Drugs 0.000 claims description 10
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
- -1 GPCR-30 Proteins 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 claims description 6
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims description 6
- 102100040385 5-hydroxytryptamine receptor 4 Human genes 0.000 claims description 6
- 101710150225 5-hydroxytryptamine receptor 4 Proteins 0.000 claims description 6
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 6
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 6
- 101710085045 B2 bradykinin receptor Proteins 0.000 claims description 6
- 102100028519 B2 bradykinin receptor Human genes 0.000 claims description 6
- 108010073466 Bombesin Receptors Proteins 0.000 claims description 6
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 claims description 6
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 claims description 6
- 102000015554 Dopamine receptor Human genes 0.000 claims description 6
- 108050004812 Dopamine receptor Proteins 0.000 claims description 6
- 102000002045 Endothelin Human genes 0.000 claims description 6
- 108050009340 Endothelin Proteins 0.000 claims description 6
- 102000011652 Formyl peptide receptors Human genes 0.000 claims description 6
- 108010076288 Formyl peptide receptors Proteins 0.000 claims description 6
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 claims description 6
- 101150037782 GAL2 gene Proteins 0.000 claims description 6
- 102100021735 Galectin-2 Human genes 0.000 claims description 6
- 102000018899 Glutamate Receptors Human genes 0.000 claims description 6
- 108010027915 Glutamate Receptors Proteins 0.000 claims description 6
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 claims description 6
- 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 claims description 6
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 claims description 6
- 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 claims description 6
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 claims description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 6
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 6
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 claims description 6
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 claims description 6
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 claims description 6
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 claims description 6
- 101710096700 P2Y purinoceptor 2 Proteins 0.000 claims description 6
- 102100028070 P2Y purinoceptor 4 Human genes 0.000 claims description 6
- 108050009478 P2Y purinoceptor 4 Proteins 0.000 claims description 6
- 102100028074 P2Y purinoceptor 6 Human genes 0.000 claims description 6
- 101710096702 P2Y purinoceptor 6 Proteins 0.000 claims description 6
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 claims description 6
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 claims description 6
- 102000002298 Purinergic P2Y Receptors Human genes 0.000 claims description 6
- 108010000818 Purinergic P2Y Receptors Proteins 0.000 claims description 6
- 102000000033 Purinergic Receptors Human genes 0.000 claims description 6
- 108010080192 Purinergic Receptors Proteins 0.000 claims description 6
- 102000005157 Somatostatin Human genes 0.000 claims description 6
- 108010056088 Somatostatin Proteins 0.000 claims description 6
- 108010072901 Tachykinin Receptors Proteins 0.000 claims description 6
- 102000007124 Tachykinin Receptors Human genes 0.000 claims description 6
- 108090000190 Thrombin Proteins 0.000 claims description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 6
- 230000005660 hydrophilic surface Effects 0.000 claims description 6
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 229940076279 serotonin Drugs 0.000 claims description 6
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 6
- 229960000553 somatostatin Drugs 0.000 claims description 6
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 6
- 229960004072 thrombin Drugs 0.000 claims description 6
- 102000011392 Galanin receptor Human genes 0.000 claims description 5
- 108050001605 Galanin receptor Proteins 0.000 claims description 5
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 claims description 5
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 claims description 5
- 102000004136 Vasopressin Receptors Human genes 0.000 claims description 5
- 108090000643 Vasopressin Receptors Proteins 0.000 claims description 5
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 5
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 claims description 3
- 101710155457 Sphingosine 1-phosphate receptor 3 Proteins 0.000 claims description 3
- 102100029803 Sphingosine 1-phosphate receptor 4 Human genes 0.000 claims description 3
- 101710155458 Sphingosine 1-phosphate receptor 4 Proteins 0.000 claims description 3
- 101150007969 ADORA1 gene Proteins 0.000 claims description 2
- 210000004671 cell-free system Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000005862 Angiotensin II Human genes 0.000 claims 2
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 claims 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 101150101769 sip5 gene Proteins 0.000 claims 1
- 102000012547 Olfactory receptors Human genes 0.000 description 52
- 108050002069 Olfactory receptors Proteins 0.000 description 52
- 102000018697 Membrane Proteins Human genes 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 239000003205 fragrance Substances 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 102400000345 Angiotensin-2 Human genes 0.000 description 10
- 238000002983 circular dichroism Methods 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 5
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000009460 calcium influx Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 238000001768 microscale thermophoresis Methods 0.000 description 5
- 102000009346 Adenosine receptors Human genes 0.000 description 4
- 108050000203 Adenosine receptors Proteins 0.000 description 4
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 4
- 239000000370 acceptor Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 108020004084 membrane receptors Proteins 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BETUMLXGYDBOLV-UHFFFAOYSA-O 2-[hydroxy(tetradecoxy)phosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C BETUMLXGYDBOLV-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 102000019432 Galanin Human genes 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000053523 human CXCR4 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161445740P | 2011-02-23 | 2011-02-23 | |
| US61/445,740 | 2011-02-23 | ||
| PCT/US2012/026353 WO2012116203A1 (en) | 2011-02-23 | 2012-02-23 | Water soluble membrane proteins and methods for the preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2827187A1 CA2827187A1 (en) | 2012-08-30 |
| CA2827187C true CA2827187C (en) | 2019-01-08 |
Family
ID=46721234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2827187A Expired - Fee Related CA2827187C (en) | 2011-02-23 | 2012-02-23 | Water soluble membrane proteins and methods for the preparation and use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US8637452B2 (enExample) |
| EP (1) | EP2709647B1 (enExample) |
| JP (1) | JP6263773B2 (enExample) |
| KR (1) | KR101963914B1 (enExample) |
| CN (2) | CN108752461A (enExample) |
| AU (3) | AU2012220558A1 (enExample) |
| BR (1) | BR112013020969A2 (enExample) |
| CA (1) | CA2827187C (enExample) |
| CL (1) | CL2013002419A1 (enExample) |
| EA (1) | EA201391041A1 (enExample) |
| IL (2) | IL227886A0 (enExample) |
| MX (1) | MX347038B (enExample) |
| SG (2) | SG192646A1 (enExample) |
| WO (1) | WO2012116203A1 (enExample) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6263773B2 (ja) | 2011-02-23 | 2018-01-24 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質およびその調製および使用方法 |
| US9700521B2 (en) | 2013-03-14 | 2017-07-11 | Massachusetts Institute Of Technology | Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies |
| WO2014176524A2 (en) | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
| US9670264B2 (en) * | 2013-04-25 | 2017-06-06 | The Trustees Of The University Of Pennsylvania | Water soluble G-protein coupled receptor |
| WO2015149085A2 (en) | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
| JP2017520862A (ja) * | 2014-03-27 | 2017-07-27 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質ならびにその調製および使用方法 |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| GB2527286A (en) * | 2014-06-11 | 2015-12-23 | Rsr Ltd | Glycoprotein hormone receptor mutations |
| WO2016025781A1 (en) | 2014-08-15 | 2016-02-18 | Cornell University | Compositions and methods for making water-soluble integral membrane proteins |
| CN104198689A (zh) * | 2014-08-25 | 2014-12-10 | 李洁 | 一种检测g-蛋白耦联受体对缩血管物质反应的方法 |
| JP7061461B2 (ja) * | 2015-02-18 | 2022-04-28 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜貫通タンパク質ならびにその調製および使用方法 |
| CN104946674B (zh) * | 2015-06-17 | 2018-05-01 | 山东大学 | 一种腺苷三磷酸/双磷酸酶及其编码基因与应用 |
| CN106749602A (zh) * | 2016-12-30 | 2017-05-31 | 武汉金开瑞生物工程有限公司 | 一种助表达序列及其在无细胞表达adcy2蛋白中的应用 |
| US11293923B2 (en) * | 2017-09-01 | 2022-04-05 | Massachusetts Institute Of Technology | S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof |
| CN111448320B (zh) * | 2017-12-11 | 2024-03-15 | 安斯泰来制药株式会社 | 细胞膜穿透肽 |
| CN108245686B (zh) * | 2018-01-15 | 2019-08-13 | 中国科学院昆明动物研究所 | 人grk5基因的用途 |
| WO2021195177A1 (en) * | 2020-03-25 | 2021-09-30 | Massachusetts Institute Of Technology | Qty fc fusion water soluble receptor proteins |
| WO2021202186A2 (en) | 2020-03-31 | 2021-10-07 | Massachusetts Institute Of Technology | Qty fc fusion receptor proteins |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US544021A (en) * | 1895-08-06 | William k | ||
| NZ240718A (en) | 1990-11-30 | 1996-10-28 | Bio Technology General Corp | Somatotropin analogues carrying mutations in the alpha-helix-1 region |
| US5739273A (en) * | 1992-02-12 | 1998-04-14 | Yale University | Transmembrane polypeptide and methods of use |
| JPH09278793A (ja) * | 1996-04-10 | 1997-10-28 | Kinichiro Miura | ポリペプチド |
| US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| WO2000053624A1 (en) * | 1999-03-11 | 2000-09-14 | Gryphon Sciences | Chemical synthesis and use of soluble membrane protein receptor domains |
| US20020160416A1 (en) | 2000-02-11 | 2002-10-31 | Boyle William J. | Receptor from TNF family |
| US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
| EP1593060A2 (en) | 2003-01-21 | 2005-11-09 | The Trustees Of The University Of Pennsylvania | Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa |
| DE102004033902A1 (de) * | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
| EP1789452B1 (en) | 2004-08-25 | 2012-04-25 | Janssen Pharmaceutica NV | Relaxin-chimeric polypeptides and their preparation and use |
| WO2006086402A2 (en) * | 2005-02-08 | 2006-08-17 | Research Development Foundation | Compositions and methods related to soluble g-protein coupled receptors(sgpcrs) |
| BRPI0502759B1 (pt) * | 2005-06-30 | 2014-02-25 | óleo lubrificante e composição lubrificante para uma máquina de refrigeração | |
| WO2007089899A2 (en) * | 2006-02-01 | 2007-08-09 | Oklahoma Medical Research Foundation | Water-soluble (g protein)-coupled receptor protein |
| WO2007141309A2 (en) | 2006-06-09 | 2007-12-13 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| EP2121919B1 (en) | 2007-03-22 | 2012-02-08 | Heptares Therapeutics Limited | Mutant g-protein coupled receptors and methods for selecting them |
| WO2008143910A2 (en) * | 2007-05-18 | 2008-11-27 | University Of Massachusetts | A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| WO2008068534A2 (en) | 2008-03-05 | 2008-06-12 | Heptares Therapeutics Limited | Crystal structure of a betal -adremergi c receptor and uses thereof |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| BR112012019540B1 (pt) | 2010-02-05 | 2021-09-28 | Heptares Therapeutics Limited | Composto, uso de um composto, formulação farmacêutica, e, processo para a preparação de um composto |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| WO2012098413A1 (en) | 2011-01-21 | 2012-07-26 | Heptares Therapeutics Limited | Mutant g-protein coupled receptor proteins and methods for producing them |
| JP6263773B2 (ja) | 2011-02-23 | 2018-01-24 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質およびその調製および使用方法 |
| WO2012120315A2 (en) | 2011-03-10 | 2012-09-13 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
| US20130273585A1 (en) | 2012-04-11 | 2013-10-17 | Gangagen, Inc. | Soluble cytoplasmic expression of heterologous proteins in escherichia coli |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| WO2015149085A2 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
| JP2017520862A (ja) | 2014-03-27 | 2017-07-27 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質ならびにその調製および使用方法 |
-
2012
- 2012-02-23 JP JP2013555565A patent/JP6263773B2/ja active Active
- 2012-02-23 CN CN201810684571.XA patent/CN108752461A/zh active Pending
- 2012-02-23 CA CA2827187A patent/CA2827187C/en not_active Expired - Fee Related
- 2012-02-23 WO PCT/US2012/026353 patent/WO2012116203A1/en not_active Ceased
- 2012-02-23 MX MX2013009715A patent/MX347038B/es active IP Right Grant
- 2012-02-23 EA EA201391041A patent/EA201391041A1/ru unknown
- 2012-02-23 US US13/403,725 patent/US8637452B2/en active Active
- 2012-02-23 CN CN2012800096906A patent/CN103458915A/zh active Pending
- 2012-02-23 SG SG2013059811A patent/SG192646A1/en unknown
- 2012-02-23 AU AU2012220558A patent/AU2012220558A1/en not_active Abandoned
- 2012-02-23 BR BR112013020969A patent/BR112013020969A2/pt not_active Application Discontinuation
- 2012-02-23 SG SG10201701547VA patent/SG10201701547VA/en unknown
- 2012-02-23 KR KR1020137024789A patent/KR101963914B1/ko active Active
- 2012-02-23 EP EP12750085.8A patent/EP2709647B1/en active Active
-
2013
- 2013-08-08 IL IL227886A patent/IL227886A0/en active IP Right Grant
- 2013-08-21 CL CL2013002419A patent/CL2013002419A1/es unknown
- 2013-12-13 US US14/105,252 patent/US9309302B2/en active Active
-
2016
- 2016-03-23 US US15/078,036 patent/US10035837B2/en active Active
- 2016-03-29 AU AU2016201914A patent/AU2016201914A1/en not_active Abandoned
-
2017
- 2017-11-15 AU AU2017261525A patent/AU2017261525A1/en not_active Abandoned
-
2018
- 2018-07-13 US US16/034,549 patent/US20180312562A1/en not_active Abandoned
- 2018-08-14 IL IL261151A patent/IL261151A/en unknown
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013020969A2 (pt) | 2018-07-10 |
| SG192646A1 (en) | 2013-09-30 |
| US10035837B2 (en) | 2018-07-31 |
| US20180312562A1 (en) | 2018-11-01 |
| EP2709647B1 (en) | 2019-08-07 |
| CN103458915A (zh) | 2013-12-18 |
| CA2827187A1 (en) | 2012-08-30 |
| IL227886A0 (en) | 2013-09-30 |
| JP6263773B2 (ja) | 2018-01-24 |
| US20160264640A1 (en) | 2016-09-15 |
| MX347038B (es) | 2017-04-10 |
| JP2014508763A (ja) | 2014-04-10 |
| AU2012220558A1 (en) | 2013-08-22 |
| US9309302B2 (en) | 2016-04-12 |
| EA201391041A1 (ru) | 2014-04-30 |
| EP2709647A4 (en) | 2015-01-21 |
| AU2016201914A1 (en) | 2016-04-21 |
| US8637452B2 (en) | 2014-01-28 |
| US20120252719A1 (en) | 2012-10-04 |
| CL2013002419A1 (es) | 2014-06-06 |
| EP2709647A1 (en) | 2014-03-26 |
| US20140243277A1 (en) | 2014-08-28 |
| CN108752461A (zh) | 2018-11-06 |
| WO2012116203A1 (en) | 2012-08-30 |
| IL261151A (en) | 2018-10-31 |
| KR101963914B1 (ko) | 2019-03-29 |
| KR20140027117A (ko) | 2014-03-06 |
| AU2017261525A1 (en) | 2017-12-07 |
| SG10201701547VA (en) | 2017-03-30 |
| MX2013009715A (es) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2827187C (en) | Water soluble membrane proteins and methods for the preparation and use thereof | |
| TWI685501B (zh) | 金屬蛋白酶第三型（ｔｉｍｐ-３）之組織抑制劑之變體、組合物及方法 | |
| Richard et al. | Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2 | |
| EP2247302B1 (en) | An engineered cxcl12 alpha locked dimer polypeptide | |
| Choi et al. | Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors | |
| Jia et al. | Toxicological effects of bisphenol A exposure-induced cancer cells migration via activating directly integrin β1 | |
| WO2015148820A1 (en) | Water-soluble membrane proteins and methods for the preparation and use thereof | |
| Zachariassen et al. | Probing the molecular interactions between CXC chemokine receptor 4 (CXCR4) and an arginine-based tripeptidomimetic antagonist (KRH-1636) | |
| US20180118806A1 (en) | Engineered replacement of partial variant water soluble membrane proteins | |
| JP4405916B2 (ja) | Ｆａｓペプチド模倣体およびその使用 | |
| JP2025172264A (ja) | 炎症性状態を処置するための方法および組成物 | |
| HK1194294B (en) | Water soluble membrane proteins and methods for the preparation and use thereof | |
| HK1194294A (en) | Water soluble membrane proteins and methods for the preparation and use thereof | |
| WO2015038891A2 (en) | Functional peptide analogs of pedf | |
| US12098175B2 (en) | Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof | |
| Jiang et al. | Conserved structure and function of chemokine CXCL8 between Chinese tree shrews and humans | |
| JP2008501620A (ja) | 細胞の生存、分化及び／又はシナプスの可塑性を調整する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130812 |
|
| MKLA | Lapsed |
Effective date: 20210831 |
|
| MKLA | Lapsed |
Effective date: 20200224 |